Jump to content

Drilldown: Medicines

Choose a table:


Medicines > routes : IM or subcutaneous & halflife: ~14 days'"`UNIQ--ref-00001103-QINU`"'

Use the filters below to narrow your results.

generic:
Adalimumab (1)
brand:
Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1)
classes:
[[:Category:Biologics|Biologic]] (1) · [[:Category:DMARDs|DMARD]] (1) · [[:Category:Immunosuppressants|Immunosuppressant]] (1) · [[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] (1) · [[:Category:TNF_inhibitors|TNF-α inhibitor]] (1)
mechanism:
'"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)
uses:
None (1)
starting dose:
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1)
preparations:
40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1)
fda max:
40 mg every week (selected indications); otherwise 40 mg every other week (1)
routes: (Click arrow to add another value)
onset:
Symptomatic effect within weeks; full response by 12-24 weeks (1)
duration:
2 weeks per dose (1)
halflife: (Click arrow to add another value)
bioavailability:
~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1)
pregnancy:
None (1)
legal:
None (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.

There are no results for this report.

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"